UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 249

Sortiert nach

Discovery of DS68702229 as a Potent, Orally Available NAMPT (Nicotinamide Phosphoribosyltransferase) Activator

Chemical and Pharmaceutical Bulletin, 2021/11/01, Vol.69(11), pp.1110-1122

2021

Volltextzugriff (PDF)

Involvement of tyrosine kinase-2 in both the IL-12/Th1 and IL-23/Th17 axes in vivo

The Journal of immunology (1950), 2011-07, Vol.187 (1), p.181-189

2011

Volltextzugriff (PDF)

Feasibility of an Ultrasound-Based Method for Measuring Talar Displacement during the Anterior Drawer Stress Test Using a Telos Device: A Preliminary Study

International journal of environmental research and public health, 2022-02, Vol.19 (4), p.2367

2022

Volltextzugriff (PDF)

A Novel Inhibitor of I-KappaB Kinase Beta Ameliorates Experimental Arthritis through Downregulation of Proinflammatory Cytokines in Arthritic Joints

Biological and Pharmaceutical Bulletin, 2014/01/01, Vol.37(1), pp.87-95

2014

Volltextzugriff (PDF)

Fission Yeast Swi1-Swi3 Complex Facilitates DNA Binding of Mrc1

The Journal of biological chemistry, 2010-12, Vol.285 (51), p.39609-39622

2010

Volltextzugriff (PDF)

Improvement of Pulmonary Function by Oral Treatment with a VLA-4 Antagonist in a Mouse Asthmatic Model

Journal of Pharmacological Sciences, 2013/02/20, Vol.121(2), pp.172-175

2013

Volltextzugriff (PDF)

Hsk1 kinase and Cdc45 regulate replication stress-induced checkpoint responses in fission yeast

Cell cycle (Georgetown, Tex.), 2010-12, Vol.9 (23), p.4627-4637

2010

Volltextzugriff (PDF)

Discovery of trans-4-[1-[[2,5-Dichloro-4-(1-methyl-3-indolylcarboxamido)phenyl]acetyl]-(4S)-methoxy-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic Acid: An Orally Active, Selective Very Late Antigen-4 Antagonist

Journal of medicinal chemistry, 2009-12, Vol.52 (24), p.7974-7992

2009

Volltextzugriff (PDF)

Identification of trans-4-[1-[[7-fluoro-2-(1-methyl-3-indolyl)-6-benzoxazolyl]acetyl]-(4S)-fluoro-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid as a potent, orally active VLA-4 antagonist

Bioorganic & medicinal chemistry, 2012-02, Vol.20 (3), p.1201-1212

2012

Volltextzugriff (PDF)

Synthesis, biological evaluation, and pharmacokinetic study of prolyl-1-piperazinylacetic acid and prolyl-4-piperidinylacetic acid derivatives as VLA-4 antagonists

Bioorganic & medicinal chemistry, 2006-04, Vol.14 (8), p.2725-2746

2006

Volltextzugriff (PDF)

Attenuation of pulmonary fibrosis in type I collagen-targeted reporter mice with ALK-5 inhibitors

Pulmonary pharmacology & therapeutics, 2019-02, Vol.54, p.31-38

2019

Volltextzugriff (PDF)

Discovery of 1-[2-(1-methyl-1H-pyrazol-5-yl)-[1,2,4]triazolo[1,5-a]pyridin-6-yl]-3-(pyridin-4-ylmethyl)urea as a potent NAMPT (nicotinamide phosphoribosyltransferase) activator with attenuated CYP inhibition

Bioorganic & medicinal chemistry letters, 2021-07, Vol.43, p.128048-128048, Article 128048

2021

Volltextzugriff (PDF)

Synthesis and biological evaluation of benzoic acid derivatives as potent, orally active VLA-4 antagonists

Bioorganic & medicinal chemistry, 2007-02, Vol.15 (4), p.1679-1693

2007

Volltextzugriff (PDF)

Optimization of NAMPT (Nicotinamide Phosphoribosyltransferase) Activators: Discovery of N,N-Diethyl-1,2-benzoxazole-3-carboxamide Derivatives as Potent NAMPT Activators with Mitigated Mutagenic Risks

Heterocycles, 2022-01, Vol.104 (1), p.94

2022

Volltextzugriff (PDF)

Identified a morpholinyl-4-piperidinylacetic acid derivative as a potent oral active VLA-4 antagonist

Bioorganic & medicinal chemistry letters, 2005-01, Vol.15 (1), p.41-45

2005

Volltextzugriff (PDF)

Investigation of the effect of hearing aid use on unilateral sensorineural hearing loss

Audiology Japan, 2024-06, Vol.67 (3), p.198-204

2024

Volltextzugriff (PDF)

4-(Pyrrolidinyl)methoxybenzoic Acid Derivatives as a Potent, Orally Active VLA-4 Antagonist

Chemical and Pharmaceutical Bulletin, 2006, Vol.54(11), pp.1515-1529

2006

Volltextzugriff (PDF)

Discovery of imidazo[1,2- b]pyridazines as IKKβ inhibitors. Part 3: Exploration of effective compounds in arthritis models

Bioorganic & medicinal chemistry letters, 2011-08, Vol.21 (15), p.4550-4555

2011

Volltextzugriff (PDF)

A novel, potent, and orally active VLA-4 antagonist with good aqueous solubility: trans-4-[1-[[2-(5-Fluoro-2-methylphenylamino)-7-fluoro-6-benzoxazolyl]acetyl]-(5S)-[methoxy(methyl)amino]methyl-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid

Bioorganic & medicinal chemistry, 2013-01, Vol.21 (1), p.42-61

2013

Volltextzugriff (PDF)

Improvement of Pulmonary Function by Oral Treatment with a VLA-4 Antagonist in a Mouse Asthmatic Model

Journal of Pharmacological Sciences, 2013-02, Vol.121 (2), p.172-175

2013

Volltextzugriff (PDF)

Discovery of imidazo[1,2- b]pyridazines as IKKβ inhibitors. Part 2: Improvement of potency in vitro and in vivo

Bioorganic & medicinal chemistry letters, 2011-02, Vol.21 (3), p.904-908

2011

Volltextzugriff (PDF)

The novel gene mus7 + is involved in the repair of replication-associated DNA damage in fission yeast

DNA repair, 2007-06, Vol.6 (6), p.770-780

2007

Volltextzugriff (PDF)

Effect of side chain location in (2-aminoethyl)aminomethyl-2-phenylquinolines as antitumor agents

Bioorganic & medicinal chemistry letters, 1998-05, Vol.8 (10), p.1243-1248

1998

Volltextzugriff (PDF)

A novel and potent VLA-4 antagonist based on trans-4-substituted cyclohexanecarboxylic acid

Bioorganic & medicinal chemistry, 2009-02, Vol.17 (3), p.1232-1243

2009

Volltextzugriff (PDF)

A novel, potent, and orally active VLA-4 antagonist with good aqueous solubility: trans-4-[1-[[2-(5-Fluoro-2-methylphenylamino)-7-fluoro-6-benzoxazo l yl]acetyl]-(5S)-[methoxy(methyl)amino]methyl-(2S)-pyrrolidinylmeth o x y]cyclohexanecarboxylic acid

Bioorganic & medicinal chemistry, 2013-01, Vol.21 (1), p.42-61

2013

Volltextzugriff (PDF)

1 – 25 von 249

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(200)
Mit Volltextzugriff
(236)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Discovery of DS68702229 as a Potent, Orally Available NAMPT (Nicotinamide Phosphoribosyltransferase) Activator

Involvement of tyrosine kinase-2 in both the IL-12/Th1 and IL-23/Th17 axes in vivo

Feasibility of an Ultrasound-Based Method for Measuring Talar Displacement during the Anterior Drawer Stress Test Using a Telos Device: A Preliminary Study

A Novel Inhibitor of I-KappaB Kinase Beta Ameliorates Experimental Arthritis through Downregulation of Proinflammatory Cytokines in Arthritic Joints

Fission Yeast Swi1-Swi3 Complex Facilitates DNA Binding of Mrc1

Improvement of Pulmonary Function by Oral Treatment with a VLA-4 Antagonist in a Mouse Asthmatic Model

Hsk1 kinase and Cdc45 regulate replication stress-induced checkpoint responses in fission yeast

Discovery of trans-4-[1-[[2,5-Dichloro-4-(1-methyl-3-indolylcarboxamido)phenyl]acetyl]-(4S)-methoxy-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic Acid: An Orally Active, Selective Very Late Antigen-4 Antagonist

Identification of trans-4-[1-[[7-fluoro-2-(1-methyl-3-indolyl)-6-benzoxazolyl]acetyl]-(4S)-fluoro-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid as a potent, orally active VLA-4 antagonist

Synthesis, biological evaluation, and pharmacokinetic study of prolyl-1-piperazinylacetic acid and prolyl-4-piperidinylacetic acid derivatives as VLA-4 antagonists

Attenuation of pulmonary fibrosis in type I collagen-targeted reporter mice with ALK-5 inhibitors

Discovery of 1-[2-(1-methyl-1H-pyrazol-5-yl)-[1,2,4]triazolo[1,5-a]pyridin-6-yl]-3-(pyridin-4-ylmethyl)urea as a potent NAMPT (nicotinamide phosphoribosyltransferase) activator with attenuated CYP inhibition

Synthesis and biological evaluation of benzoic acid derivatives as potent, orally active VLA-4 antagonists

Optimization of NAMPT (Nicotinamide Phosphoribosyltransferase) Activators: Discovery of N,N-Diethyl-1,2-benzoxazole-3-carboxamide Derivatives as Potent NAMPT Activators with Mitigated Mutagenic Risks

Identified a morpholinyl-4-piperidinylacetic acid derivative as a potent oral active VLA-4 antagonist

Investigation of the effect of hearing aid use on unilateral sensorineural hearing loss

4-(Pyrrolidinyl)methoxybenzoic Acid Derivatives as a Potent, Orally Active VLA-4 Antagonist

Discovery of imidazo[1,2- b]pyridazines as IKKβ inhibitors. Part 3: Exploration of effective compounds in arthritis models

A novel, potent, and orally active VLA-4 antagonist with good aqueous solubility: trans-4-[1-[[2-(5-Fluoro-2-methylphenylamino)-7-fluoro-6-benzoxazolyl]acetyl]-(5S)-[methoxy(methyl)amino]methyl-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid

Improvement of Pulmonary Function by Oral Treatment with a VLA-4 Antagonist in a Mouse Asthmatic Model

Discovery of imidazo[1,2- b]pyridazines as IKKβ inhibitors. Part 2: Improvement of potency in vitro and in vivo

The novel gene mus7 + is involved in the repair of replication-associated DNA damage in fission yeast

Effect of side chain location in (2-aminoethyl)aminomethyl-2-phenylquinolines as antitumor agents

A novel and potent VLA-4 antagonist based on trans-4-substituted cyclohexanecarboxylic acid

A novel, potent, and orally active VLA-4 antagonist with good aqueous solubility: trans-4-[1-[[2-(5-Fluoro-2-methylphenylamino)-7-fluoro-6-benzoxazo l yl]acetyl]-(5S)-[methoxy(methyl)amino]methyl-(2S)-pyrrolidinylmeth o x y]cyclohexanecarboxylic acid

Suchergebnisse filtern